MRKMerck

Ranked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)

• 🔥🔥🔥#1▲0.69%DirectMRK 8-K — Results of Operations and Financial Condition39d ago

  The filing itself carries little new info; despite an 18.8% average beat, recent quarters decelerated to +0.49%/+9.32%, so upside hinges on Keytruda growth and 2028 patent-cliff guidance

  Impact chain →

  Also named: BMY · PFE

• 🔥🔥#2▲0.43%DirectThe Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.9d ago

  As Moderna's partner and Keytruda co-administration party, Merck's scale dilutes the impact of any single pipeline headline

  Impact chain →

  Also named: MRNA · BNTX · PSNL · ADPT · ILMN · TMO

• 🔥#3▲0.4%DirectMRK 10-Q — Quarterly report36d ago

  Filing confirms steady +5.1% revenue, $7.3 EPS and $18.3B net income, but modest growth in a routine disclosure is largely already priced

  Impact chain →

  Also named: PFE · BMY

• #4▲0.35%DirectAI & Robotics in 2026: 16 Recent Developments for Investors3d ago

  Listed as a beneficiary of AI-assisted drug discovery, providing a mild positive sentiment effect without any concrete earnings change.

  Impact chain →

  Also named: CBRS · CRWD · NET · NVDA · PANW · MRNA

• #5▼0.24%2nd-orderHUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China13d ago

  Tepotinib faces added competition from savolitinib's first-line combination in the MET space, though China exposure is limited

  Impact chain →

  Also named: HCM · AZN · NVS